Equities
Health CareMedical Equipment and Services
  • Price (GBX)1,162.50
  • Today's Change-13.50 / -1.15%
  • Shares traded2.33m
  • 1 Year change+10.87%
  • Beta0.9550
Data delayed at least 20 minutes, as of Sep 18 2024 16:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.29bn
  • Net income in GBP231.76m
  • Incorporated1937
  • Employees18.00k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SN.:LSE since
announced
Transaction
value
Cartiheal 2009 LtdDeal completed22 Nov 202322 Nov 2023Deal completed13.75%330.00m
Data delayed at least 20 minutes, as of Sep 18 2024 16:53 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ypsomed Holding AG491.92m70.29m5.16bn2.30k73.419.3137.5310.495.745.7440.1845.260.55875.404.96238,875.007.984.4112.406.8134.4727.2614.297.380.596720.890.29320.5010.253.8652.835.448.6429.46
Amplifon SpA1.96bn136.44m5.24bn14.38k38.325.4513.972.670.71530.715310.275.030.622921.4610.96161,594.304.334.316.535.8124.5659.016.957.280.39926.120.592134.266.6510.66-12.219.0812.6815.68
Demant A/S2.53bn299.68m7.11bn21.50k23.706.55--2.8111.9810.92101.2343.360.71922.035.681,034,778.008.528.2711.6813.2375.4574.1411.8511.341.065.580.62440.0013.8910.0012.236.968.80--
Smith & Nephew plc4.29bn231.76m10.28bn18.00k44.312.6014.042.400.26540.26544.914.520.55350.71284.30232,345.702.994.103.624.9969.0471.395.418.021.115.480.412579.596.402.5017.94-16.884.241.85
BioMerieux SA3.21bn347.31m10.74bn14.65k31.053.2818.043.343.463.4632.0432.800.73561.825.63259,811.607.719.309.5712.3155.7256.5110.4812.381.20236.140.125817.762.398.70-20.956.878.3619.42
Sartorius AG2.82bn65.53m13.86bn14.14k170.214.9231.934.911.141.1449.1739.290.39341.759.19228,602.701.518.212.0511.8344.1750.933.8414.151.052.200.548219.59-18.6616.74-69.747.7419.143.66
Sartorius Stedim Biotech SA2.32bn142.88m14.92bn10.38k101.334.5438.686.431.791.7929.2239.950.41451.758.84257,644.002.6111.873.0415.1241.8250.966.3117.441.032.950.426618.73-20.5318.02-64.658.2821.823.90
Data as of Sep 18 2024. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

33.92%Per cent of shares held by top holders
HolderShares% Held
BlackRock Investment Management (UK) Ltd.as of 16 Feb 202445.46m5.20%
Cevian Capital ABas of 02 Jul 202443.90m5.02%
Wellington Management Co. LLPas of 31 Dec 202042.67m4.88%
The Vanguard Group, Inc.as of 02 Sep 202437.04m4.24%
Norges Bank Investment Managementas of 02 Sep 202427.57m3.15%
Norges Bank Investment Management (UK)as of 28 Jun 202426.70m3.05%
BlackRock Fund Advisorsas of 02 Sep 202421.23m2.43%
Walter Scott & Partners Ltd.as of 02 Sep 202419.25m2.20%
UBS Asset Management (UK) Ltd.as of 02 Sep 202416.70m1.91%
Legal & General Investment Management Ltd.as of 02 Sep 202416.04m1.84%
More ▼
Data from 30 Jun 2024 - 12 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.